Fenofibrate can 'downgrade' Covid-19 threat to common cold l
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A widely used anti-cholesterol drug, fenofibrate, can "downgrade" the danger-level of coronavirus to that of a common cold, a Hebrew University (HU) academic has claimed.

The two researchers focussed on the ways in which SARS-CoV-2 changes patients' lungs in order to reproduce itself.

They discovered that the virus prevents the routine burning of carbohydrates. As a result, large amounts of fat accumulate inside lung cells, a condition the virus needs in order to reproduce.

"This new understanding of SARS CoV-2 may help explain why patients with high blood sugar and cholesterol levels are often at a particularly high risk to develop COVID-19," they noted.

Having drawn this conclusion, the two researchers began to screen FDA-approved medications that interfere with the virus' ability to reproduce.

In their lab studies, the cholesterol-lowering drug fenofibrate, sold under the brand name Tricor, showed extremely promising results.

By allowing lung cells to burn more fat, fenofibrate breaks the virus' grip on these cells and prevents SARS CoV-2's ability to reproduce. In fact, within only five days of treatment, the virus almost completely disappeared, the researchers claim.

Source: https://www.nationalheraldindia.com/india/hebrew-university-researcher-claims-existing-drug-can-downgrade-covid-threat-to-common-cold-level
Dr. U●●●s B●●●●●●●r and 30 others like this27 shares